Guest Blog By: Meranda Honaker
Over the last several months my health has continued to decline despite being compliant and diligent with my healthcare routine. In July I developed a fever during a trip to Boston to speak to a biotech company about my journey with cystic fibrosis. I developed a fever and by the end of my visit, I was unable to walk up steps without severe dyspnea. I was so exhausted from feeling sick I would return to my hotel room to lay in the bed for hours to rest. My chest pain and shortness of breath became so severe in the coming days that I could no longer take a deep breath. I checked my SpiroPd home spirometer which displayed a definite decline in my lung function. I immediately contacted my CF clinic to see my CF doctor. Initially, despite feeling bad, I assumed I was feeling poorly and decided not to rush to CF clinic. Sometimes I have a bad day or few bad days health wise and begin to improve on my own. Once I saw my lung function had declined I knew I needed to be seen in CF clinic rather than waiting it out.
Continue reading Home Spirometers: A Useful Tool in Tracking CF Symptoms and Progress
Canadian scientists have discovered a possible way to break through the defences of some antibiotic-resistant respiratory infections.
It’s hoped that the findings could someday benefit people with cystic fibrosis and other chronic lung diseases who are at greater risk of infections. Continue reading Scientists find new way to attack antibiotic-resistant lung infections
TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections. Continue reading New Drug to Help with Resistant Fungal Lung Infections
The updated guidelines focus on the diagnosis and treatment of the major forms of aspergillosis: allergic, chronic and invasive, the latter which kills 40 percent to 80 percent of those with widespread infection. Continue reading Early diagnosis, effective therapy vital for treatment of deadly invasive aspergillosis
Pulmatrix, Inc. (NASDAQ: PULM) announced today that its Chief Scientific Officer, David L. Hava, PhD, has written an article in ONdrugDelivery Magazine highlighting advances in delivering drugs to the lungs to fight Continue reading Advances in Inhaled Drug Delivery Offer Major Benefits to Patients, Chief Scientific Officer for Pulmatrix Explains in Article
Cystic fibrosis (CF) affects about 30,000 Americans leaving them with a variety of symptoms ranging from gastrointestinal problems to the more recognized respiratory complications. The condition is caused by a mutation Continue reading LOSING TO WIN: HOW FUNGI CAUSE TROUBLE IN CYSTIC FIBROSIS
Drug Resistance Updates, 08/28/2015Verweij PE, et al.
Intravenous therapy with either micafungin or L–AmB given as either intermittent or continuous therapy was recommended for chronic pulmonary Continue reading International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus
Cystic fibrosis patients suffer from chronic bacterial infections and thick mucous in their lungs, due largely to a combination of microbial infections and resulting inflammation. A common pathogen, Continue reading Bacterial food web may be key to cystic fibrosis
Science/AAAS | News
Fatal weakness. Pathogens such as methicillin-resistant Staphylococcus aureus (above) develop vulnerabilities as they evolve resistance to antibiotics. Choosing antibiotics that exploit these weaknesses can thwart resistant bacteria. Continue reading If Chosen Wisely, Existing Drugs Fight Resistant Bugs